SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 6 analyzed stories

Boston Scientific (BSX) Q3 Sales $5.14B; Cuts FY26 Outlook

Boston Scientific reported third-quarter 2026 net sales of $5.14B, GAAP EPS of $0.40 and adjusted EPS of $0.73. The company cut its full-year 2026 outlook and guided fourth-quarter sales down about 1% to 3%.

Published:

Updated:

What happened

Boston Scientific reported third-quarter 2026 net sales of $5.14 billion, up 1.5% from a year earlier, with adjusted earnings per share of $0.73 versus $0.75 previously. The company lowered its full-year 2026 outlook and guided fourth-quarter sales down about 1% to 3%.

Global impact / market context

The company sold slightly more than a year ago but earned less per share on an adjusted basis, and it now expects slower growth ahead. For ordinary investors, this means the business is still growing but at a weaker pace than previously expected, and the coming quarter may bring a sales decline.

What to watch

  1. Check whether fourth-quarter sales actually fall about 1% to 3% as guided, because that would confirm the slowdown the company flagged.
  2. Check whether full-year 2026 reported sales growth lands near the about 4.25% outlook, because missing it would signal demand is weaker than guided.
  3. Check whether full-year 2026 organic sales growth lands near the about 3.75% outlook, because organic sales strip out currency swings and acquisitions and show underlying demand.

Affected assets

  • Boston Scientific Corporation

Evidence